Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This article describes the finding of substantial upregulation of mRNA and enzymes of the cytochrome P450 1A family during a lead optimization campaign for small molecule S1P1 agonists. Fold changes in mRNA up to 10,000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for CYP1A1 and CYP1A2 in vitro in rat and human hepatocytes were observed. Challenges observed with correlating induction in vitro and induction in vivo resulted in the implementation of a short, 4 day in vivo screening study in the rat which successfully identified noninducers. Subtle structure-activity relationships in this series of S1P1 agonists are described extending beyond planarity and lipophilicity, and the impact and considerations of AhR and CYP1A induction in the context of drug development are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.5b01102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Novel β-Arrestin Biased Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
J Med Chem
September 2025
Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
Fingolimod, the first nonselective S1P modulator for multiple sclerosis (MS), is effective but linked to cardiovascular side effects. To improve the drug safety profile, we developed β-arrestin biased S1P agonists with reduced G-protein activity using a pharmacophore-based approach. Among them, compound showed 4.
View Article and Find Full Text PDFActivation of S1PR1 by Ponesimod for Multiple Sclerosis Therapy: Uncovering MAPK and PI3K Pathway Mechanisms and Repurposing Potential.
Chemistry
August 2025
School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing, 100081, China.
Multiple sclerosis (MS), affecting over 2 million people globally, primarily causes neurological disability in individuals under 40. This autoimmune disorder involves the immune system attacking the myelin sheath in the central nervous system. Sphingosine-1-phosphate receptor 1 (S1PR1) is a promising therapeutic target, with approved drugs like ponesimod acting as S1PR1 agonists.
View Article and Find Full Text PDFInflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak.
J Biol Chem
August 2025
Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Inflammation disrupts endothelial barrier function and causes vascular leak into the tissue parenchyma. Sphingosine 1-phosphate receptor-1 (S1PR1) in endothelial cells (ECs) is a key inducer of endothelial junctions and barrier function. We report here that ECs activation by the cytokine TNFα and TLR3 agonist polyinosine/polycytosine (pI:C) induces the lymphocyte activation molecule CD69 via the canonical NFκB pathway.
View Article and Find Full Text PDFSepsis is a life-threatening disease characterized by multiorgan dysfunction caused by an abnormal immune response to microbial infection. Sphingosine-1-phosphate (S1P) levels are significantly lower in patients with sepsis and are negatively correlated with the severity of sepsis. However, whether the S1P signaling pathway is a target for sepsis treatment remains unknown.
View Article and Find Full Text PDFSEW2871 attenuates myocyte necroptosis in heart failure through inhibition of oxidative stress and inflammatory cytokines.
Br J Pharmacol
June 2025
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background And Purpose: Sphingosine-1-phosphate (S1P)/S1P receptor signalling exerts cardioprotective effects. However, the effect of the selective S1P receptor agonist SEW2871 on myocyte necroptosis in heart failure and the underlying mechanisms are unknown. In the present study, we tested the hypothesis that SEW2871 attenuates myocyte necroptosis in heart failure through inhibition of oxidative stress and inflammatory cytokines.
View Article and Find Full Text PDF